NSE
Anthem Biosciences LimitedANTHEM
Anthem Biosciences Limited is an Indian pharmaceutical company engaged in the development, manufacturing, and marketing of generic drugs.
| Key products | Generic drugs |
|---|---|
| Geography | India |
| Competitors | Dr Reddy's Laboratories, Cipla |
AI-generated overview — verify before relying on it.
Net institutional flow
No institutional deals
Institutional buyers
0 in / 0 out
High-impact filings
0 · tilt Neutral
Next corporate action
Dividend - Rs 2 Per Share
ex 2026-06-25
| # | Company | Inst. flow ₹Cr | Deals | Hi-impact | Filing mom. | Buzz | News |
|---|---|---|---|---|---|---|---|
| 1 | ANTHEMThis | — | — | — | — | — | — |
| 2 | 360ONE | — | — | — | — | +9 | 22 |
| 3 | 3MINDIA | — | — | — | — | — | — |
| 4 | ACC | — | — | — | — | — | — |
| 5 | AIAENG | — | — | — | — | +13 | 20 |
| 6 | APLAPOLLO | — | — | — | — | — | — |
| 7 | AUBANK | +₹0 Cr | 2 | — | — | — | — |
| 8 | AWL | — | — | — | — | — | — |
| 9 | ABBOTINDIA | — | — | — | — | +2 | 17 |
Ranked by net institutional flow (buys − sells, ₹Cr). Filing momentum = bullish − bearish filings; Buzz = news+social sentiment. Curate peers in the company admin.
SWOT
Strengths
- • Strong presence in the Indian market
- • Diversified portfolio of generic drugs
- • Research and Development capabilities
- • Established partnerships with international companies
Weaknesses
- • Dependence on a few key products
- • High competition from established players
- • Regulatory challenges in India
- • Limited global presence
Opportunities
- • Growing demand for affordable medicines in emerging markets
- • Increasing focus on biosimilars and complex generics
- • Partnerships with innovative companies for new product development
- • Expansion into new therapeutic areas such as oncology and rare diseases
Threats
- • Compliance risks due to regulatory changes
- • Increased competition from generic versions of branded drugs
- • Volatility in raw material prices and supply chain management
- • Risks associated with product recalls and quality control issues
AI-generated from our data — verify before relying on it.
- 2026-06-25ActionDividend - Rs 2 Per ShareDividend
- 2026-06-17FilingThe Exchange has sought clarification from Anthem Biosciences Limited for the quarter ended 31-Mar-2026 with rResults
- 2026-06-16FilingAnthem Biosciences Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) and 31 (5Shareholding Disclosure
Merged from deals, filings, corporate actions and news — newest first. Compact rolls each day up to net flow + counts. Scope with the range above.
Filings that matter
- 2
- 2Shareholding DisclosureNeutral
a copy of Disclosure under Regulation 31(4) and 31 (5) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
Source PDF →
No bulk/block deals for ANTHEM in this window.
Results & transcripts
Calls & transcripts
None yet.
News & chatter on ANTHEM
RSS News
0No recent news.
Google News RSS — links open the source.
Investdesk
0No articles yet.
Our coverage.
No Reddit chatter.
r/ posts mentioning the company.
Twitter / X
0No posts.
Posts mentioning the company.